Sign in
Taking peoplePhase 4

ASPIRING

Key facts

Who runs it
University Of Edinburgh
Where
Belgium and Netherlands28 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
596 people, planned
Started
7 Oct 2025
Expected to end
1 Aug 2030
Type of study
Interventional
Record updated
7 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Stroke due to intracerebral haemorrhage (ICH), diagnosed by brain imaging, with symptom onset at least 24 hours before randomisation
  • Age ≥18 years at the time of first imaging diagnosis of ICH
  • Radiological text report of the brain imaging study that first diagnosed the ICH is available
  • Consent obtained from the participant (or their representative if the participant lacks mental capacity)

Who cannot take part

  • Previously enrolled in ASPIRING
  • Oral antiplatelet or oral anticoagulant drug, or aspirin over the counter, were taken within 24 hours before randomisation
  • Investigator believes that prescription of a daily oral antiplatelet drug is required at the time of randomisation
  • Antiplatelet drug use is contraindicated
  • ICH (intracerebral haemorrhage) exclusively caused by head injury
  • ICH secondary to aneurysm, angiitis, arteriovenous malformation/fistula, cavernous malformation, coagulopathy, intracranial venous thrombosis, moyamoya disease, or tumour
  • Pregnant, breast-feeding, or of child-bearing potential and not using highly effective contraception
  • Enrolled in a study that precludes co-enrolment with ASPIRING
  • ICH due to hemorrhagic transformation of cerebral infarction
  • Systolic blood pressure (BP) ≥160mmHg at randomisation
  • Death appears imminent
  • Follow-up will not be possible for the primary and secondary outcomes

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

ASPIRING will test the hypothesis that starting oral antiplatelet drug monotherapy is superior to avoiding antiplatelet drugs, in addition to standard care at the participating hospital, for increasing the time to first major adverse cardiovascular or cerebrovascular events (MACE) for survivors of stroke due to intracerebral haemorrhage (ICH).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe - SM
Record updated
7 May 2026